A Randomized, Double-Blind, Placebo-Controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Apixaban (Primary)
  • Indications Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Jun 2009 In order to focus investigation on the 5 mg/day dosage, randomisation to the 10 and 20 mg/day arms was discontinued after the recruitment of 125 patients, according to information presented at ASCO 2009.
    • 02 Jun 2009 Results from the first 125 patients were presented at ASCO 2009.
    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top